Current Report Filing (8-k)
February 04 2022 - 7:08AM
Edgar (US Regulatory)
false 0001347178 0001347178 2022-02-04 2022-02-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2022
VANDA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-34186
|
|
03-0491827
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (202) 734-3400
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001
per share
|
|
VNDA
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On February 4, 2022, Vanda Pharmaceuticals Inc. issued a press release regarding the results from the Phase III clinical study of tradipitant in gastroparesis. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Dated: February 4, 2022
|
|
|
|
VANDA PHARMACEUTICALS INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Timothy Williams
|
|
|
|
|
Name:
|
|
Timothy Williams
|
|
|
|
|
Title:
|
|
Senior Vice President, General Counsel
and Secretary
|
Vanda Pharmaceuticals (NASDAQ:VNDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
Historical Stock Chart
From Apr 2023 to Apr 2024